Table 2.
Comparison of children treated and not treated with remdesivir
| entire study group (n = 328) | treated with remdesivir (n = 64; 19.51%) | not treated with remdesivir (n = 264; 80.49%) | p | ||
|---|---|---|---|---|---|
| age, y, median (range) | 4 (0.7–11) | 3.8 (0.8–10.3) | 4 (0.7–11) | 0.58 | |
| sex, girls:boys | 141: 187 | 26: 38 | 115: 149 | 0.66 | |
| immunodeficiency | 118 (35.98%) | 28 (43.75%) | 88 (33.33%) | 0.12 | |
| vaccination (any doses) | 7 (2.1%) | 0 | 7 (2.65%) | 0.67 | |
| course of COVID-19 | |||||
| asymptomatic | 106 (32.32%) | 10 (15.63%) | 96 (36.36%) | < 0.01 | |
| mild | 170 (51.83%) | 24 (37.50%) | 146 (55.30%) | ||
| moderate | 22 (6.71%) | 13 (20.31%) | 9 (3.41%) | ||
| severe | 23 (7.01%) | 13 (20.31%) | 10 (3.79%) | ||
| critical | 7 (2.13%) | 4 (6.25%) | 3 (1.14%) | ||
| adverse outcomes | |||||
| pneumonia | 48 (14.63%) | 24 (37.50%) | 24 (9.10%) | < 0.01 | |
| oxygen therapy | 39 (11.89%) | 22 (34.38%) | 17 (6.44%) | < 0.01 | |
| hospitalization in the ICU | 9 (2.74%) | 5 (7.82%) | 4 (1.52%) | 0.01 | |
| death | 5 (1.52%) | 3 (4.69%) | 2 (0.76%) | 0.02 | |
| symptoms | |||||
| fever | 167 (50.91%) | 43 (67.19%) | 124 (46.97%) | < 0.01 | |
| cough | 94 (28.66%) | 31 (48.44%) | 63 (23.86%) | < 0.01 | |
| dyspnea | 42 (12.80%) | 22 (34.38%) | 20 (7.58%) | < 0.01 | |
| vomiting | 35 (10.67%) | 8 (12.5%) | 27 (10.23%) | 0.66 | |
| diarrhea | 27 (8.23%) | 3 (4.69%) | 24 (9.10%) | 0.24 | |
| time of hospitalization, days, median (range) | 8 (4–13) | 12 (7–15) | 7 (4–11) | < 0.01 | |
| time to negative antigen test result, days, median (range) | 9 (12–16) | 7 (11–14) | 10 (13–18) | 0.08 | |
Italic entries reflect statistical significance (p < 0.05)
COVID-19 Coronavirus Disease 2019, ICU intensive care unit